Eris Lifesciences (ERIS) Corporate presentation summary

Business overview and growth strategy

• Achieved top-20 status among Indian pharma companies in under 20 years, with 80% of revenue from super-specialty segments.

• Expanded into dermatology, injectables, and biologics through over INR 4,300 cr. in acquisitions from FY23–FY26.

• Presence in 70+ countries, with a shift from India-centric to global B2B and CDMO models.

• Six manufacturing units with global accreditations, supporting a wide range of dosage forms and technologies.

• Strategic investments in diabesity and injectables, with capex of INR 750–800 cr. planned for FY26–FY28.

Financial performance and integration

• Revenue grew from INR 1,347 cr. in FY22 to INR 2,894 cr. in FY25, with EBITDA margin expanding from 32% to 36%.

• Operating cash flow averaged 75% of EBITDA, with FY25 OCF at 105% of EBITDA.

• EPS remained flat from FY22–FY25 due to amortization and tax changes, but is expected to accelerate from FY26.

• Net debt to EBITDA reduced from ~4x in FY24 to ~2x in 9M FY26, targeting <1.5x by Dec 2026.

Domestic branded formulations and market leadership

• Expanded addressable market by 77% from Apr 2023 to Dec 2025, reaching Rs. 1,23,600 cr.

• Holds top-5 position in anti-diabetes therapy with 6% market share and 16% share in insulins.

• Tripled RHI cartridge market share since acquisition, aiming for 25% share in insulins.

• Launched multiple successful brands leveraging loss of exclusivity opportunities.